Agilent launches new SureSelect Human All-Exon UTRs

Agilent Technologies has announced the launch of a pair of new untranslated regions (UTRs) for use in next-generation sequencing.

The SureSelect Human All-Exon V5 and V5 Plus UTRs incorporate the latest advances from Agilent Genomics and enable faster turnaround-producing exome samples that can be ready for sequencing within a day.

Because they are optimised to provide maximum specificity and sensitivity, these new solutions require only 4 Gb of total sequencing – up to 60 percent less than alternative human exome offerings.

These new products are part of the SureSelect portfolio and are available as a complete SureSelectXT or SureSelectXT2 solution.

Kathleen Shelton, Agilent's senior marketing director for genomics, said: "We are excited to continue delivering high-performance exome target capture products. Our V5 and V5 Plus UTRs are the most up-to-date and comprehensive exome kits available."

Last week, the company agreed an exclusive deal to provide continued service to users of Roche's NimbleGen microarrays, which are soon to be made defunct by their manufacturer.